BIVI Forecast


Bullish Case: BIVI's upcoming trial results for Alzheimer’s treatment could lead to FDA approval, triggering significant investor optimism and a potential price surge.


Bearish Case: Continued poor performance in trials and broader market decline may lead to further stock depreciation, reflecting investor skepticism and reduced interest.


Potential Outcomes:

1. Breakthrough Alzheimer’s drug approval: 20%

2. Negative trial results: 35%

3. Continued market decline: 45%. These probabilities incorporate volatility and historical performance indicators.


Trading Oracle: Sign Up to access trading oracle trade ideas.


July 25, 2024


BioVie Forecast

BIVI      BioVie











Correlated Assets

Assets that tend to move strongly with BIVI



LI Forecast + Options Trading Strategies   LI  Li Auto (0.85)


VFC Forecast + Options Trading Strategies   VFC  VF (0.74)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (-0.48)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.9)



Uncorrelated Assets

Assets with little price relationship to BIVI



XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (-0.48)


VFC Forecast + Options Trading Strategies   VFC  VF (0.74)


LI Forecast + Options Trading Strategies   LI  Li Auto (0.85)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.9)



Anticorrelated Assets

Assets that tend to move strongly against BIVI



LI Forecast + Options Trading Strategies   LI  Li Auto (0.85)


VFC Forecast + Options Trading Strategies   VFC  VF (0.74)


XLE Forecast + Options Trading Strategies   XLE  Energy Select Sector SPDR (-0.48)


ETRN Forecast + Options Trading Strategies   ETRN  Equitrans Midstream (-0.9)





Become a more profitable investor with AI optimized trading strategies






×

Chat with BIVI


 Ask any question about BIVI!